Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 7, 2021; 27(21): 2895-2909
Published online Jun 7, 2021. doi: 10.3748/wjg.v27.i21.2895
Table 1 Clinicopathological characteristics of 232 patients with gastric neuroendocrine carcinoma and univariate analysis
Classification
n
Median survival time/mo
P value
Age (yr)0.26
< 608012.56 (9.42-14.57)
≥ 60 15214.85 (11.80-18.11)
Gender0.32
Male19114.50 (11.78-16.21)
Female4111.50 (7.94-12.05)
Tumor number0.01
Solitary514.02 (11.93-16.06)
Multiple2145.98 (3.40-6.60)
NR13NRNR
Tumor diameter (cm)0.01
0-510518.10 (9.35-20.64)
> 59911.50 (9.41-16.58)
NR28NRNR
Invasion0.02
M1/S/MP28216.27 (12.51-17.49)
Serosa11611.54 (7.54-14.54)
NR34NRNR
Tumor site0.09
Cardia6516.12 (11.53-18.46)
Fundus1519.88 (3.99-28.00)
Body3315.98 (9.46-20.53)
Antrum2711.80 (8.73-17.26)
C + F3512.50 (7.96-16.03)
Other4015.23 (8.59-23.40)
NR17NRNR
Pathological type0.68
Large cell NEC4112.96 (12.11-13.84)
Small cell NEC2616.33 (11.30-20.69)
MANEC3812.33 (8.80-15.19)
NR12714.31 (10.40-17.59)
Ki-67 index0.61
20%-50%6012.69 (7.50-16.49)
50%-70%11414.10 (11.74-16.25)
> 70%3813.23 (0.00-26.80)
NR20NR NR
Endoscopic performance0.90
Polypoid715.00 (11.85-16.14)
Mucosal elevation2817.19 (6.99-25.00)
Ulcer 15713.69 (10.66-15.33)
Other4011.00 (9.09-10.90)
Tumor N staging0.16
N05020.00 (5.30-30.70)
N1-N317413.11 (9.95-16.00)
NR8NRNR
Distant metastasis< 0.001
No15717.43 (12.94-21.05)
Yes7311.64 (9.04-12.95)
NR2NRNR
AJCC stage< 0.001
I588.26 (36.06-139.94)
II2531.34 (13.56-48.43)
III11316.12 (13.43-18.56)
IV8611.52 (9.05-12.94)
NR3NR NR
Treatment0.01
Surgery8615.47 (10.87-19.12)
Chemotherapy4012.10 (10.24-13.75)
Surgery + chemotherapy9215.70 (9.99-20.00)
Other1411.00 (0.00-21.68)